Tenecteplase; Modified Tissue plasminogen activator (tPA)

Specification

• Cat#: THP-0020
• Product Name: Tenecteplase; Modified Tissue plasminogen activator (tPA)
• Cas No: 191588-94-0
• Description: Tissue plasminogen activator (tPA). The product is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain.
• Sequences: SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGNWSTAESGAECTNWQSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAAAAASPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP
• Species: Human
• Molecular Weight: 58951.2 Da
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: C2561H3919N747O781S40
• Endotoxin: <0.001 EU per 1 μg by the LAL method
• Biological Activity: 8KU/vial
• Application: For treatment of myocardial infarction and lysis of intracoronary emboli.

Pharmaceutical Information

• Pharmaceutical Application: Tenecteplase
• Targets: Target 1. Plasminogen; Target 2. Fibrinogen alpha chain; Target 3. Urokinase plasminogen activator surface receptor; Target 4. Plasminogen activator inhibitor 1; Target 5. Plasminogen activator inhibitor 2; Target 6. Tetranectin; Target 7. Keratin, type II cytoskeletal 8; Target 8. Annexin A2; Target 9. Calreticulin; Target 10. Calnexin; Target 11. Prolow-density lipoprotein receptor-related protein 1